AI assistant
Entrada Therapeutics, Inc. — Director's Dealing 2021
Oct 29, 2021
33674_dirs_2021-10-28_f7ea3cd1-5775-4a48-9055-eba137ce3d56.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Entrada Therapeutics, Inc. (TRDA)
CIK: 0001689375
Period of Report: 2021-10-28
Reporting Person: WENTWORTH KORY JAMES (Chief Financial Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 9535 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $2.10 | 2030-11-10 | Common Stock (116196) | Direct | |
| Stock Option (Right to Buy) | $8.47 | 2031-05-20 | Common Stock (54251) | Direct | |
| Stock Option (Right to Buy) | $12.52 | 2031-08-02 | Common Stock (31764) | Direct |
Footnotes
F1: Represents 9,535 shares of restricted common stock issued upon early exercise of stock options.
F2: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3: 25% of the shares subject to this option shall vest and become exercisable on March 30, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F4: 25% of the shares subject to this option shall vest and become exercisable on August 2, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.